Formulary Watch |

All News - Page 4

FDA Approves Iclusig for New Patients with Aggressive Leukemia
FDA Approves Iclusig for New Patients with Aggressive Leukemia
FDA Approves Iclusig for New Patients with Aggressive Leukemia
March 19, 2024
The accelerated approval of Iclusig for patients with acute lymphoblastic leukemia and with the Philadelphia chromosome was based on a surrogate endpoint. Iclusig has a list price of $20,831 for 30 tablets.
Payers Question CMS’ Ability to Get Discounts Though Drug Price Negotiation
Payers Question CMS’ Ability to Get Discounts Though Drug Price Negotiation
Payers Question CMS’ Ability to Get Discounts Though Drug Price Negotiation
March 19, 2024
In a recent survey, payers said the Inflation Reduction Act will help lower patients’ out-of-pocket costs, but they were concerned about Medicare’s drug price negotiation and the IRA’s impact on formulary management.
Sebastian Kaulitzki-stock.adobe.com
FDA Approves Rezdiffra, First Drug for NASH
FDA Approves Rezdiffra, First Drug for NASH
March 15, 2024
Madrigal Pharmaceuticals is pricing Rezdiffra (resmetirom) at wholesale acquisition price of $47,400 per year.
FDA Approves Livmarli for Second Liver Disease Indication
FDA Approves Livmarli for Second Liver Disease Indication
FDA Approves Livmarli for Second Liver Disease Indication
March 14, 2024
Livmarli is now approved to treat the itching associated two different rare liver diseases: progressive familial intrahepatic cholestasis and Alagille syndrome.
Prime Therapeutics and Capital Rx Create Technology Alliance
Prime Therapeutics and Capital Rx Create Technology Alliance
Prime Therapeutics and Capital Rx Create Technology Alliance
March 13, 2024
The new collaboration gives Prime access to Capital Rx’s secure claims system JUDI, which Capital Rx leaders say was developed with enhanced security protocols.
Artur-stock.adobe.com
Michigan is First Medicaid Program to Offer Lyfgenia for Sickle Cell
Michigan is First Medicaid Program to Offer Lyfgenia for Sickle Cell
March 11, 2024
Michigan’s state Medicaid agency has signed an outcomes-based agreement for Lyfgenia patients with sickle cell disease. The agreement provides payers with risk sharing tied to vaso-occlusive events-related hospitalizations
FDA to hold Advisory Committee on Donanemab in Alzheimer’s Disease
FDA to hold Advisory Committee on Donanemab in Alzheimer’s Disease
FDA to hold Advisory Committee on Donanemab in Alzheimer’s Disease
March 8, 2024
Regulators want to discuss safety issues, as well as the phase 3 trial’s design where patients were treated based on an assessment of amyloid plaque and the inclusion of patients based on tau protein levels.
FDA Approves Second Biosimilar of Actemra
FDA Approves Second Biosimilar of Actemra
FDA Approves Second Biosimilar of Actemra
March 7, 2024
The new biosimilar, Tyenne, was approved in both an IV and a subcutaneous forms to treat inflammatory conditions such as arthritis.
Can a Netflix Model Work for Gene Therapy?
Can a Netflix Model Work for Gene Therapy?
Can a Netflix Model Work for Gene Therapy?
March 6, 2024
Quantile Health is offering a new solution to help small health plans and self-insured employers fund gene therapy access — with a subscription model.
7activestudio-stock.adobe.com
Ozempic Reduces Kidney Disease Progression, Cardiovascular Events by 24%
Ozempic Reduces Kidney Disease Progression, Cardiovascular Events by 24%
March 5, 2024
The FLOW trial was stopped early based on an interim analysis that found the study met the criteria for efficacy.
Ophthalmologists Face Insurance Issues when Using Biosimilars
Ophthalmologists Face Insurance Issues when Using Biosimilars
Ophthalmologists Face Insurance Issues when Using Biosimilars
March 4, 2024
Fran Gregory, Pharm.D., of Cardinal Health, talks about a survey of ophthalmologists and their concerns about using biosimilars for retinal conditions.
© 2024 MJH Life Sciences

All rights reserved.